Deep Targeted Sequencing Of TP53 In Chronic Ly... - CLL Support
Deep Targeted Sequencing Of TP53 In Chronic Lymphocytic Leukemia: Clinical Impact At Diagnosis And At Time Of Treatment
You need to be a member of this community to see this post.
Read more about...
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
Chronic Lymphocytic Leukemia: USA Updates in Diagnosis and Testing
Over the past decade, diagnosis, testing, and prognostic stratification have substantially...
Chronic lymphocytic leukemia treatment algorithm 2022
This 29 November 2022 review article published in the Blood Cancer Journal presents an...
Acalabrutinib Plus Venetoclax and Obinutuzumab Achieves High Bone Marrow uMRD Rate in Chronic Lymphocytic Leukemia - CLL
Great news from this long awaited first published phase 2 study reporting the efficacy of this AVO...
Association of gene mutations with time‐to‐first treatment in 384 treatment‐naive chronic lymphocytic leukaemia patients
First published: 26 June 2019 in BJH - full paper behind a paywall unfortunately
This study...
SF3B1 Mutations
We've had a couple of members mention that they are positive for SF3B1 Mutations so I thought it...
Related Posts
- Potential Early Drivers of Disease in Treatment-Naive CLL Identified
- Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with CLL
- Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in CLL? - Dr Keating
- Use of MRD Status Following Obinutuzumab/Ibrutinib to Guide Subsequent Intensification of Therapy in CLL
- "Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
